| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 25,469 | 24,309 | ||
| General and administrative | 7,475 | 7,143 | ||
| Total operating expenses | 32,944 | 31,452 | ||
| Loss from operations | -32,944 | -31,452 | ||
| Interest and other income, net | 3,076 | 3,354 | ||
| Total other income | 3,076 | 3,354 | ||
| Net loss | -29,868 | -28,098 | ||
| Unrealized gain (loss) on marketable securities available-for-sale, net | 6 | -252 | ||
| Comprehensive loss | -29,862 | -28,350 | ||
| Net loss per share, basic | -0.5 | -0.47 | ||
| Net loss per share, diluted | -0.5 | -0.47 | ||
| Weighted average number of shares outstanding, basic | 59,670,757 | 59,550,771 | ||
| Weighted average number of shares outstanding, diluted | 59,670,757 | 59,550,771 | ||
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)